Navigation Links
Scientists discover how Ebola virus infects cells

Ebola virus reproduction in laboratory-grown cells is severely hampered by enzyme-inhibiting chemicals, and these chemicals deserve further study as possible treatments for Ebola virus infections in humans, report scientists supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).

The researchers, whose paper is published online today in Science Express, identified two cellular enzymes Ebola virus must have to reproduce. When those enzymes are blocked, the virus loses most of its infectivity, the scientists found.

Ebola virus, like the Marburg virus now alarming Angola, is a filovirus, a family of viruses that cause severe and frequently fatal hemorrhagic fevers. "Finding medical countermeasures for viral hemorrhagic fevers is a global public health priority because not only do these diseases occur naturally but they also have the potential to be unleashed by bioterrorists," says NIH Director Elias A. Zerhouni, M.D.

"This new research sheds light on the mechanism Ebola virus uses to enter cells," notes NIAID Director Anthony S. Fauci, M.D. "These findings raise the possibility of a broad-spectrum antiviral therapy that could be effective against multiple hemorrhagic fever viruses."

Senior author James M. Cunningham, M.D., of Brigham and Women's Hospital and Harvard Medical School in Boston, and his colleagues discovered two cellular enzymes that the Ebola virus co-opts and uses to cut up one of the virus' surface proteins. Once this protein is snipped apart, the virus is free to begin multiplying. The scientists applied broad-spectrum enzyme inhibitors to mammalian cells before exposing them to Ebola virus. When one specific cellular enzyme, cathepsin B, was inhibited, the infectivity of Ebola virus dropped to near zero. An accessory role is played by another cellular enzyme, cathepsin L, the scientists determined.

Inhibitors of cathepsins ar e already under clinical development as anti-cancer drugs. The authors write, "Further investigation of the antiviral efficacy of [enzyme] inhibitors may…be warranted. The wealth of existing knowledge regarding the design and in vivo pharmacology of these inhibitors may facilitate development of an anti-Ebola-virus therapy."

Reference: K Chandran et al. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science Express. Published online April 14, 2005. DOI: 10.1126/science.1110656.



Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. Scientists discover the cellular roots of graying hair
10. Scientists rid stem cell culture of key animal cells
11. Scientists develop new color-coded test for protein folding
Post Your Comments:

(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... an innovator in modern authentication and a founding member ... launch of its latest version of the Nok Nok™ ... to use standards-based authentication that supports existing and emerging ... Suite is ideal for organizations deploying customer-facing applications that ...
(Date:10/22/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics software ... September 30, 2015.  --> --> ... a decrease of 33% compared to $6.0 million in the same ... was $2.2 million, or $0.10 per diluted share, which compared to ... a year ago.  --> --> ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... ... ... This fall, global software solutions leader SAP and AdVenture Capital brought together ... their BIG ideas to improve health and wellness in their schools. , Now, the ... title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, and ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
Breaking Biology Technology: